MASLD and MASH defined
MASLD (metabolic-dysfunction-associated steatotic liver disease) is excess fat in the liver in the setting of metabolic dysfunction (obesity, insulin resistance, diabetes, dyslipidemia). It affects an estimated 25-30% of global adults. About 20% of MASLD progresses to MASH (steatohepatitis), fat plus inflammation and hepatocyte injury. MASH can progress to fibrosis, cirrhosis, and hepatocellular carcinoma.
Until recently, the only treatment was lifestyle modification. GLP-1 therapy is changing this.
Trial data
Major findings:
- Semaglutide trials (2.4 mg weekly) showed 30-60% reduction in liver fat by MRI-PDFF
- MASH resolution in 30-60% of patients in dedicated trials
- Tirzepatide trials show similar or superior efficacy
- Liver enzymes (ALT, AST) typically normalize within months
- Effect tracks weight loss but exceeds it (direct hepatic effects evident)
Mechanism
Multiple contributors to liver fat reduction:
- Weight loss reduces overall fat mass and visceral fat specifically
- Improved insulin sensitivity reduces hepatic de novo lipogenesis
- Reduced lipid delivery to liver from improved metabolic state
- Reduced inflammation, directly affects hepatic inflammation
- Possibly direct GLP-1 effects on hepatocytes (though receptor density is low; mostly indirect)
Tirzepatide superiority
The dual GLP-1/GIP receptor activation of tirzepatide produces greater weight loss and metabolic improvement than GLP-1 alone, which translates to greater hepatic benefit. The SYNERGY-NASH trial of tirzepatide in MASH showed superior MASH resolution rates compared to historical GLP-1 mono-agonist data.
Liver enzyme improvements
Patients with elevated baseline ALT, AST, or GGT typically see substantial reductions on GLP-1 therapy:
- ALT often drops 30-50% by 6 months
- AST drops similarly (slower than ALT)
- GGT drops, particularly if alcohol intake also decreases
Normalization of liver enzymes is a clean lab-visible signal of therapeutic effect.
Effects on fibrosis
Liver fibrosis is the structural change that distinguishes uncomplicated fatty liver from progressive disease. GLP-1 therapy:
- Reduces inflammation, which drives fibrosis
- Reverses some fibrosis in trials, though improvement in fat is faster than improvement in fibrosis
- Longer-duration treatment increasingly shows fibrosis improvement
Patients with significant baseline fibrosis (F2-F3) may need longer treatment for visible structural improvement.
Monitoring
For patients with MASLD/MASH on GLP-1 therapy:
- Liver enzymes (ALT, AST, GGT) every 3-6 months
- FibroScan or other elastography to track fibrosis annually
- For high fibrosis stages: hepatology co-management
- OPTML metabolic panels capture liver enzymes routinely
The clinical pearl: Liver enzyme normalization on GLP-1 therapy is one of the most reliable lab-visible benefits. For patients with elevated baseline ALT/AST who didn't know they had fatty liver, the improvement is often the first concrete sign that therapy is working at the metabolic level.
Bottom line
GLP-1 therapy reduces liver fat substantially and resolves MASH in many patients. The mechanism is multi-factorial, weight loss, insulin sensitivity, inflammation reduction. For patients with metabolic dysfunction and fatty liver, GLP-1 therapy is now first-line treatment alongside lifestyle modification.